STOCK TITAN

Ideaya Biosciences - IDYA STOCK NEWS

Welcome to our dedicated page for Ideaya Biosciences news (Ticker: IDYA), a resource for investors and traders seeking the latest updates and insights on Ideaya Biosciences stock.

Overview of IDEAYA Biosciences

IDEAYA Biosciences Inc. (IDYA) is a precision medicine oncology company that specializes in discovering and developing targeted therapeutics for genetically defined patient populations. By leveraging advanced molecular diagnostics and synthetic lethality, the company identifies cancer vulnerabilities and develops small molecule therapies aimed at interfering with DNA damage repair and tumor microenvironment interactions. IDEAYA operates at the intersection of drug discovery and translational biomarker validation, positioning itself as a key entity in the evolving field of precision medicine.

Core Business Areas and Approach

IDEAYA’s core business is built on its unique approach to oncology drug discovery. The company focuses on:

  • Synthetic Lethality: Exploiting vulnerabilities in the DNA damage and repair mechanisms specific to certain tumor genotypes, thereby enabling targeted therapeutic interventions.
  • Precision Medicine: Utilizing molecular diagnostics and translational biomarkers to select patients most likely to benefit from its therapies, ensuring personalized treatment strategies.
  • Innovative Drug Discovery: Integrating small molecule discovery with advanced computational methodologies and physics-based approaches to unravel previously undruggable targets.

Market Position and Differentiation

IDEAYA stands out in the competitive oncology landscape due to its robust drug discovery process and its strategic focus on precision therapies. The company has assembled a world-class team of scientists and advisors, including Nobel laureates and national academy members, which underscores its deep expertise and authority in the biotech industry. Furthermore, its collaborations with industry giants and academic partners boost its R&D capabilities and enhance its credibility in developing transformative therapeutic candidates.

Clinical Pipeline and Strategic Collaborations

IDEAYA’s extensive clinical-stage pipeline addresses multiple oncology targets using innovative mechanisms. Its product candidates are designed to exploit synthetic lethality in various biomarker-defined patient groups. The company is actively advancing candidates that target key proteins and enzymes involved in tumor DNA repair and epigenetic regulation. Strategic collaborations with leading pharmaceutical companies not only share the risk and cost of development but also provide access to advanced research and regulatory expertise.

Scientific and Operational Excellence

Backed by a solid foundation of scientific research and rigorous due diligence during drug development, IDEAYA demonstrates a commitment to operational excellence. Its integrated approach couples pioneering laboratory research with state-of-the-art computational methods, ensuring that its innovative candidates are robustly validated preclinically before entering clinical trials. This methodical process helps build trust among stakeholders and supports its long-term potential as an innovator in precision oncology.

Implications in Precision Oncology

Through its focus on genetically defined patient populations, IDEAYA addresses an unmet need in the treatment of cancers with specific molecular profiles. Investors, analysts, and industry experts find value in understanding how the company’s unique focus on synthetic lethality and translational biomarker development may offer differentiated outcomes compared to traditional approaches. The company’s rigorous, data-driven methodology provides clear insights into the complex dynamics of oncogenic pathways, reinforcing its reputation as a knowledgeable and respected player in the biotech community.

Conclusion

In summary, IDEAYA Biosciences exemplifies a next-generation precision medicine approach in oncology. With its strategically developed pipeline, strong scientific foundation, and collaborative industry partnerships, the company is well positioned to contribute meaningfully to advancements in targeted cancer therapeutics, fostering better patient outcomes through innovative science and technology.

Rhea-AI Summary

IDEAYA Biosciences (NASDAQ: IDYA) announced the publication of abstracts for its synthetic lethality programs at the 2023 AACR Annual Meeting. The company will present data on IDE397, a MAT2A inhibitor, and IDE161, a PARG inhibitor, both in Phase 1/2 trials, along with a preclinical Werner Helicase program. Notable presentations include dual inhibition of MAT2A and PRMT5, and targeting HRD breast and ovarian tumors. IDEAYA is collaborating with Amgen and GSK for these programs. The company aims for further clinical developments and eligibility for up to $10 million in milestone payments in connection with its Werner Helicase program.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.64%
Tags
none
-
Rhea-AI Summary

IDEAYA Biosciences reported a strong cash position of approximately $373.1 million as of December 31, 2022, sufficient to fund operations into 2026. The company is advancing its lead program, darovasertib, targeting ocular melanoma, with regulatory updates anticipated after a Q1 2023 FDA meeting. Clinical updates for darovasertib are expected mid-year 2023, aiming for an overall response rate >20% and a median progression-free survival >5 months. IDEAYA also plans IND submissions for IDE161 and Pol Theta Helicase candidates in 2023, alongside collaborations with GSK and Amgen to expand its pipeline.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.17%
Tags
-
Rhea-AI Summary

IDEAYA Biosciences (NASDAQ: IDYA) announced its participation in two key investor conferences in March 2023. The first is the Oppenheimer 33rd Annual Healthcare Conference on March 14, where CSO Michael White and CMO Darrin Beaupre will engage in a fireside chat. The second is the Guggenheim 4th Annual Healthy Altitudes Summit on March 15, featuring CEO Yujiro S. Hata. Live audio webcasts will be available on IDEAYA's website, with replays accessible for 30 days post-event. The company is committed to developing targeted therapeutics using molecular diagnostics, focusing on synthetic lethality in oncology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.3%
Tags
conferences
Rhea-AI Summary

IDEAYA Biosciences (NASDAQ: IDYA), a precision medicine oncology company, will participate in Citi's 2023 Virtual Oncology Leadership Summit on February 21, 2023, at 9:00 AM ET. The event features a fireside chat with President and CEO Yujiro S. Hata, hosted by Dr. Yigal D. Nochomovitz. Investors can access a live audio webcast via IDEAYA's website, with a replay available for 30 days after the event.

IDEAYA focuses on synthetic lethality and targeted therapeutics, using molecular diagnostics to identify patient populations that benefit from its innovative therapies. The company is dedicated to advancing precision medicine in oncology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.35%
Tags
conferences
-
Rhea-AI Summary

IDEAYA Biosciences, Inc. (NASDAQ: IDYA) announced its participation in the 2023 Guggenheim Oncology Conference, scheduled for February 9, 2023, at 7:45 AM PT. The event will feature a fireside chat with President and CEO Yujiro S. Hata and Chief Scientific Officer Michael White, hosted by equity research analyst Charles Zhu, Ph.D. A live audio webcast of the discussion will be available on IDEAYA's website, with a replay accessible for 30 days post-event. IDEAYA focuses on synthetic lethality and precision medicine, developing targeted therapeutics based on molecular diagnostics to enhance treatment efficacy for selected patient populations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.35%
Tags
conferences
-
Rhea-AI Summary

IDEAYA Biosciences has initiated a Phase 2 clinical trial to evaluate darovasertib as a neoadjuvant treatment for uveal melanoma (UM) before primary therapies like enucleation or radiation. The study focuses on eye preservation, reduced radiation, and functional vision. With an annual incidence of about 8,700 cases in the US and EU, UM presents a significant unmet medical need. The trial protocol allows for darovasertib treatment for up to six months, followed by primary treatment and adjuvant therapy. Clinical data updates, particularly on darovasertib combined with crizotinib for metastatic UM, are anticipated in 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.15%
Tags
Rhea-AI Summary

IDEAYA Biosciences announced FDA clearance for its IND application, enabling the Phase 1 clinical trial of IDE161, a novel PARG inhibitor for tumors with homologous recombination deficiencies (HRD), particularly in breast and ovarian cancer patients with BRCA mutations. Dosing is set to commence in Q1 2023, starting at half the estimated efficacious dose from preclinical studies. The trial focuses on ER+/Her2- breast cancer, constituting 10-14% of cases. IDEAYA will present IDE161's profile at the J.P. Morgan Healthcare Conference on January 10, 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.07%
Tags
-
Rhea-AI Summary

IDEAYA Biosciences (NASDAQ: IDYA) announced its participation in the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023. The event will feature a presentation by CEO Yujiro S. Hata at 4:30 pm PT (7:30 pm ET), followed by a Q&A session hosted by Anupam Rama. Investors can access a live audio webcast on IDEAYA's website, with a replay available for 30 days post-event. IDEAYA is focused on precision medicine and developing targeted therapeutics using molecular diagnostics, emphasizing synthetic lethality in oncology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.35%
Tags
conferences
-
Rhea-AI Summary

IDEAYA Biosciences (Nasdaq: IDYA) has appointed Dr. Karlene Cimprich and Dr. Kornelia Polyak to its Scientific Advisory Board. Dr. Cimprich, from Stanford University, specializes in replication stress mechanisms and DNA damage repair pathways relevant to cancer therapeutics. Dr. Polyak, from Dana-Farber Cancer Institute, focuses on breast cancer biology and clinical management. This expansion aims to enhance IDEAYA's expertise in synthetic lethality and advance its precision medicine oncology pipeline, particularly the clinical evaluation of IDE161, a potential first-in-class PARG inhibitor.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
management
Rhea-AI Summary

IDEAYA Biosciences has submitted an Investigational New Drug (IND) application to the FDA for IDE161, a potential first-in-class PARG inhibitor targeting homologous recombination deficiency in BRCA1/2-mutant breast and ovarian cancers. This submission marks a significant milestone in IDEAYA's approach to addressing the unmet medical need for patients resistant to current PARP inhibitors. The proposed clinical development plan will be discussed in an Investor R&D Day webcast on December 12, 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.13%
Tags
none

FAQ

What is the current stock price of Ideaya Biosciences (IDYA)?

The current stock price of Ideaya Biosciences (IDYA) is $15.57 as of April 3, 2025.

What is the market cap of Ideaya Biosciences (IDYA)?

The market cap of Ideaya Biosciences (IDYA) is approximately 1.4B.

What is the primary focus of IDEAYA Biosciences?

IDEAYA Biosciences focuses on precision medicine in oncology, using synthetic lethality and molecular diagnostics to develop targeted therapeutics for genetically defined patient populations.

How does IDEAYA differentiate itself in the oncology market?

IDEAYA differentiates itself by integrating advanced small molecule drug discovery with translational biomarker validation, supported by a world-class scientific team and strategic collaborations with major industry partners.

Which innovative approaches does IDEAYA employ in its drug development?

The company utilizes a combination of synthetic lethality, computational drug discovery, and high-throughput screening methods to identify and develop therapies that target specific cancer vulnerabilities.

What types of diseases are targeted by IDEAYA's therapeutics?

IDEAYA targets various oncological conditions, focusing on tumors defined by genetic mutations and molecular signatures related to DNA damage and repair mechanisms.

How does IDEAYA ensure that its therapies reach the right patient populations?

By employing molecular diagnostics and translational biomarker strategies, IDEAYA selects patient populations that are most likely to benefit from its targeted therapies, ensuring a precision medicine approach.

What role do strategic partnerships play for IDEAYA?

Strategic partnerships with leading pharmaceutical companies and academic institutions enhance IDEAYA’s research capabilities, support its clinical development, and help in mitigating risks associated with drug discovery.

Can you explain the term 'synthetic lethality' in the context of IDEAYA's work?

Synthetic lethality refers to targeting cancer-specific vulnerabilities by inhibiting compensatory pathways in tumor cells, a strategy that IDEAYA applies to develop therapies for patients with certain genetic profiles.

How does IDEAYA contribute to advancements in precision oncology?

IDEAYA contributes by leveraging its deep scientific expertise and novel drug discovery approaches, developing innovative therapies that address unique oncogenic mechanisms, thus potentially improving patient outcomes.
Ideaya Biosciences

Nasdaq:IDYA

IDYA Rankings

IDYA Stock Data

1.43B
86.63M
1.04%
109.56%
10.5%
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO